Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- 01 May 2017 Planned End Date changed from 1 Jun 2020 to 1 May 2020.
- 01 May 2017 Planned primary completion date changed from 1 Jun 2020 to 1 May 2020.
- 01 May 2017 Status changed from not yet recruiting to recruiting.